Crescent Biopharma (CBIO) Asset Utilization Ratio (2014 - 2026)

Crescent Biopharma (CBIO) posted quarterly Asset Utilization Ratio of 0.01 for Q2 2026, up 15.07% quarter-over-quarter from 0.0 in Q1 2026.

Crescent Biopharma (CBIO) Asset Utilization Ratio (2014 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has reported Asset Utilization Ratio for 9 consecutive years, with 0.01 the latest figure, recorded in Q2 2026.

In Q2 2026, Asset Utilization Ratio changed N/A year-over-year to 0.01; the TTM figure through Jun 2026 stood at 0.01 (changed N/A YoY), while the FY2025 annual figure was 0.08, changed N/A from the prior year.
Asset Utilization Ratio rose to 0.01 in Q2 2026 per CBIO's latest filing, from 0.0 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.01 in Q2 2026 and bottomed at 0.0 in Q4 2022.
Historically, Asset Utilization Ratio has averaged 0.0 across 3 years, with a median of 0.0 in 2022.
On a YoY basis, Asset Utilization Ratio climbed as much as 73.64% in 2022 and fell as far as 85.52% in 2022.
Crescent Biopharma's Asset Utilization Ratio stood at 0.0 in 2022, then soared by 70.06% to 0.0 in 2024, then soared by 86.15% to 0.01 in 2026.
Business Quant data shows CBIO's Asset Utilization Ratio at 0.01 in Q2 2026, 0.0 in Q1 2026, and 0.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.19 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.58 Bn	77.59 Bn	3.93 Bn	0.38
3	Argenx Se	64.52 Bn	59.34 Bn	1.37 Bn	-
4	Moderna	56.52 Bn	51.38 Bn	52.00 Mn	0.20
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	30.67 Bn	27.36 Bn	992.69 Mn	0.90
7	Insmed	27.27 Bn	26.11 Bn	358.27 Mn	0.54
8	BioNTech SE	27.14 Bn	8.75 Bn	668.28 Mn	0.13
9	Royalty Pharma	27.12 Bn	26.28 Bn	-	0.13
10	Crescent Biopharma	1.06 Bn	885.92 Mn	-	0.01

Download Data